Baseline serum uric acid level is associated with progression-free survival, disease control rate, and safety in postoperative patients with colorectal cancer treated by FOLFOX, FOLFIRI, or XELOX
BackgroundHigh serum uric acid (SUA) levels increase the risk of overall cancer morbidity and mortality, particularly for digestive malignancies. Nevertheless, the correlation between SUA level and clinical outcomes of the postoperative patients with colorectal cancer (CRC) treated by chemotherapy i...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-07-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.918088/full |
| _version_ | 1818162476293816320 |
|---|---|
| author | Xi Zhang Xi Zhang Qing-hong Chen Ying Yang Jing-xin Lin Yan-chun Li Tian-yu Zhong Jie Chen Si-qi Wu Xiao-hu Chen Rui-si Zhou Jia-man Lin Dong-qing Wang Qiu-xing He Yan-ting You Xing-hong Zhou Qiang Zuo Yan-yan Liu Jing-ru Cheng Yi-fen Wu Xiao-shan Zhao |
| author_facet | Xi Zhang Xi Zhang Qing-hong Chen Ying Yang Jing-xin Lin Yan-chun Li Tian-yu Zhong Jie Chen Si-qi Wu Xiao-hu Chen Rui-si Zhou Jia-man Lin Dong-qing Wang Qiu-xing He Yan-ting You Xing-hong Zhou Qiang Zuo Yan-yan Liu Jing-ru Cheng Yi-fen Wu Xiao-shan Zhao |
| author_sort | Xi Zhang |
| collection | DOAJ |
| description | BackgroundHigh serum uric acid (SUA) levels increase the risk of overall cancer morbidity and mortality, particularly for digestive malignancies. Nevertheless, the correlation between SUA level and clinical outcomes of the postoperative patients with colorectal cancer (CRC) treated by chemotherapy is unclear. This study aimed at exploring the relationship between baseline SUA level and progression-free survival (PFS), disease control rate (DCR), and safety in postoperative CRC patients receiving chemotherapy.Patients and MethodsWe conducted a retrospective study to evaluate the relationship between baseline SUA level and PFS, DCR, and incidence of serious adverse events of 736 postoperative CRC patients treated with FOLFOX, FOLFIRI or XELOX at our center.ResultsData from our center suggested that high baseline SUA level is linked to poor PFS in non-metastatic CRC patients using FOLFOX (HR=2.59, 95%CI: 1.29-11.31, p=0.018) and in male patients using FOLFIRI (HR=3.77, 95%CI: 1.57-39.49, p=0.012). In patients treated by FOLFIRI, a high SUA is also linked to a low DCR (p=0.035). In patients using FOLFOX, high baseline SUA level is also linked to a high incidence of neutropenia (p=0.0037). For patients using XELOX, there is no significant correlation between SUA level and PFS, effectiveness, or safety.ConclusionsThese findings imply that a high SUA level is a promising biomarker associated with poor PFS, DCR and safety of postoperative CRC patients when treated with FOLFOX or FOLFIRI. |
| first_indexed | 2024-12-11T16:34:16Z |
| format | Article |
| id | doaj.art-a6909da1c24f47e38e800ce28a44dc98 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-11T16:34:16Z |
| publishDate | 2022-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-a6909da1c24f47e38e800ce28a44dc982022-12-22T00:58:31ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-07-011210.3389/fonc.2022.918088918088Baseline serum uric acid level is associated with progression-free survival, disease control rate, and safety in postoperative patients with colorectal cancer treated by FOLFOX, FOLFIRI, or XELOXXi Zhang0Xi Zhang1Qing-hong Chen2Ying Yang3Jing-xin Lin4Yan-chun Li5Tian-yu Zhong6Jie Chen7Si-qi Wu8Xiao-hu Chen9Rui-si Zhou10Jia-man Lin11Dong-qing Wang12Qiu-xing He13Yan-ting You14Xing-hong Zhou15Qiang Zuo16Yan-yan Liu17Jing-ru Cheng18Yi-fen Wu19Xiao-shan Zhao20Syndrome Laboratory of Integrated Chinese and Western Medicine, School of Chinese Medicine, Southern Medical University, Guangzhou, ChinaDepartment of Oncology, Affiliated Dongguan People’s Hospital, Southern Medical University, Dongguan, ChinaSyndrome Laboratory of Integrated Chinese and Western Medicine, School of Chinese Medicine, Southern Medical University, Guangzhou, ChinaSyndrome Laboratory of Integrated Chinese and Western Medicine, School of Chinese Medicine, Southern Medical University, Guangzhou, ChinaSyndrome Laboratory of Integrated Chinese and Western Medicine, School of Chinese Medicine, Southern Medical University, Guangzhou, ChinaDepartment of Nephrology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaSyndrome Laboratory of Integrated Chinese and Western Medicine, School of Chinese Medicine, Southern Medical University, Guangzhou, ChinaSyndrome Laboratory of Integrated Chinese and Western Medicine, School of Chinese Medicine, Southern Medical University, Guangzhou, ChinaSyndrome Laboratory of Integrated Chinese and Western Medicine, School of Chinese Medicine, Southern Medical University, Guangzhou, ChinaSyndrome Laboratory of Integrated Chinese and Western Medicine, School of Chinese Medicine, Southern Medical University, Guangzhou, ChinaSyndrome Laboratory of Integrated Chinese and Western Medicine, School of Chinese Medicine, Southern Medical University, Guangzhou, ChinaSyndrome Laboratory of Integrated Chinese and Western Medicine, School of Chinese Medicine, Southern Medical University, Guangzhou, ChinaSyndrome Laboratory of Integrated Chinese and Western Medicine, School of Chinese Medicine, Southern Medical University, Guangzhou, ChinaSyndrome Laboratory of Integrated Chinese and Western Medicine, School of Chinese Medicine, Southern Medical University, Guangzhou, ChinaSyndrome Laboratory of Integrated Chinese and Western Medicine, School of Chinese Medicine, Southern Medical University, Guangzhou, ChinaSyndrome Laboratory of Integrated Chinese and Western Medicine, School of Chinese Medicine, Southern Medical University, Guangzhou, ChinaDepartment of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, ChinaSyndrome Laboratory of Integrated Chinese and Western Medicine, School of Chinese Medicine, Southern Medical University, Guangzhou, ChinaDepartment of Nephrology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Oncology, Affiliated Dongguan People’s Hospital, Southern Medical University, Dongguan, ChinaSyndrome Laboratory of Integrated Chinese and Western Medicine, School of Chinese Medicine, Southern Medical University, Guangzhou, ChinaBackgroundHigh serum uric acid (SUA) levels increase the risk of overall cancer morbidity and mortality, particularly for digestive malignancies. Nevertheless, the correlation between SUA level and clinical outcomes of the postoperative patients with colorectal cancer (CRC) treated by chemotherapy is unclear. This study aimed at exploring the relationship between baseline SUA level and progression-free survival (PFS), disease control rate (DCR), and safety in postoperative CRC patients receiving chemotherapy.Patients and MethodsWe conducted a retrospective study to evaluate the relationship between baseline SUA level and PFS, DCR, and incidence of serious adverse events of 736 postoperative CRC patients treated with FOLFOX, FOLFIRI or XELOX at our center.ResultsData from our center suggested that high baseline SUA level is linked to poor PFS in non-metastatic CRC patients using FOLFOX (HR=2.59, 95%CI: 1.29-11.31, p=0.018) and in male patients using FOLFIRI (HR=3.77, 95%CI: 1.57-39.49, p=0.012). In patients treated by FOLFIRI, a high SUA is also linked to a low DCR (p=0.035). In patients using FOLFOX, high baseline SUA level is also linked to a high incidence of neutropenia (p=0.0037). For patients using XELOX, there is no significant correlation between SUA level and PFS, effectiveness, or safety.ConclusionsThese findings imply that a high SUA level is a promising biomarker associated with poor PFS, DCR and safety of postoperative CRC patients when treated with FOLFOX or FOLFIRI.https://www.frontiersin.org/articles/10.3389/fonc.2022.918088/fulluric acidcolorectal cancerprognosisdisease control ratesafety |
| spellingShingle | Xi Zhang Xi Zhang Qing-hong Chen Ying Yang Jing-xin Lin Yan-chun Li Tian-yu Zhong Jie Chen Si-qi Wu Xiao-hu Chen Rui-si Zhou Jia-man Lin Dong-qing Wang Qiu-xing He Yan-ting You Xing-hong Zhou Qiang Zuo Yan-yan Liu Jing-ru Cheng Yi-fen Wu Xiao-shan Zhao Baseline serum uric acid level is associated with progression-free survival, disease control rate, and safety in postoperative patients with colorectal cancer treated by FOLFOX, FOLFIRI, or XELOX Frontiers in Oncology uric acid colorectal cancer prognosis disease control rate safety |
| title | Baseline serum uric acid level is associated with progression-free survival, disease control rate, and safety in postoperative patients with colorectal cancer treated by FOLFOX, FOLFIRI, or XELOX |
| title_full | Baseline serum uric acid level is associated with progression-free survival, disease control rate, and safety in postoperative patients with colorectal cancer treated by FOLFOX, FOLFIRI, or XELOX |
| title_fullStr | Baseline serum uric acid level is associated with progression-free survival, disease control rate, and safety in postoperative patients with colorectal cancer treated by FOLFOX, FOLFIRI, or XELOX |
| title_full_unstemmed | Baseline serum uric acid level is associated with progression-free survival, disease control rate, and safety in postoperative patients with colorectal cancer treated by FOLFOX, FOLFIRI, or XELOX |
| title_short | Baseline serum uric acid level is associated with progression-free survival, disease control rate, and safety in postoperative patients with colorectal cancer treated by FOLFOX, FOLFIRI, or XELOX |
| title_sort | baseline serum uric acid level is associated with progression free survival disease control rate and safety in postoperative patients with colorectal cancer treated by folfox folfiri or xelox |
| topic | uric acid colorectal cancer prognosis disease control rate safety |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.918088/full |
| work_keys_str_mv | AT xizhang baselineserumuricacidlevelisassociatedwithprogressionfreesurvivaldiseasecontrolrateandsafetyinpostoperativepatientswithcolorectalcancertreatedbyfolfoxfolfiriorxelox AT xizhang baselineserumuricacidlevelisassociatedwithprogressionfreesurvivaldiseasecontrolrateandsafetyinpostoperativepatientswithcolorectalcancertreatedbyfolfoxfolfiriorxelox AT qinghongchen baselineserumuricacidlevelisassociatedwithprogressionfreesurvivaldiseasecontrolrateandsafetyinpostoperativepatientswithcolorectalcancertreatedbyfolfoxfolfiriorxelox AT yingyang baselineserumuricacidlevelisassociatedwithprogressionfreesurvivaldiseasecontrolrateandsafetyinpostoperativepatientswithcolorectalcancertreatedbyfolfoxfolfiriorxelox AT jingxinlin baselineserumuricacidlevelisassociatedwithprogressionfreesurvivaldiseasecontrolrateandsafetyinpostoperativepatientswithcolorectalcancertreatedbyfolfoxfolfiriorxelox AT yanchunli baselineserumuricacidlevelisassociatedwithprogressionfreesurvivaldiseasecontrolrateandsafetyinpostoperativepatientswithcolorectalcancertreatedbyfolfoxfolfiriorxelox AT tianyuzhong baselineserumuricacidlevelisassociatedwithprogressionfreesurvivaldiseasecontrolrateandsafetyinpostoperativepatientswithcolorectalcancertreatedbyfolfoxfolfiriorxelox AT jiechen baselineserumuricacidlevelisassociatedwithprogressionfreesurvivaldiseasecontrolrateandsafetyinpostoperativepatientswithcolorectalcancertreatedbyfolfoxfolfiriorxelox AT siqiwu baselineserumuricacidlevelisassociatedwithprogressionfreesurvivaldiseasecontrolrateandsafetyinpostoperativepatientswithcolorectalcancertreatedbyfolfoxfolfiriorxelox AT xiaohuchen baselineserumuricacidlevelisassociatedwithprogressionfreesurvivaldiseasecontrolrateandsafetyinpostoperativepatientswithcolorectalcancertreatedbyfolfoxfolfiriorxelox AT ruisizhou baselineserumuricacidlevelisassociatedwithprogressionfreesurvivaldiseasecontrolrateandsafetyinpostoperativepatientswithcolorectalcancertreatedbyfolfoxfolfiriorxelox AT jiamanlin baselineserumuricacidlevelisassociatedwithprogressionfreesurvivaldiseasecontrolrateandsafetyinpostoperativepatientswithcolorectalcancertreatedbyfolfoxfolfiriorxelox AT dongqingwang baselineserumuricacidlevelisassociatedwithprogressionfreesurvivaldiseasecontrolrateandsafetyinpostoperativepatientswithcolorectalcancertreatedbyfolfoxfolfiriorxelox AT qiuxinghe baselineserumuricacidlevelisassociatedwithprogressionfreesurvivaldiseasecontrolrateandsafetyinpostoperativepatientswithcolorectalcancertreatedbyfolfoxfolfiriorxelox AT yantingyou baselineserumuricacidlevelisassociatedwithprogressionfreesurvivaldiseasecontrolrateandsafetyinpostoperativepatientswithcolorectalcancertreatedbyfolfoxfolfiriorxelox AT xinghongzhou baselineserumuricacidlevelisassociatedwithprogressionfreesurvivaldiseasecontrolrateandsafetyinpostoperativepatientswithcolorectalcancertreatedbyfolfoxfolfiriorxelox AT qiangzuo baselineserumuricacidlevelisassociatedwithprogressionfreesurvivaldiseasecontrolrateandsafetyinpostoperativepatientswithcolorectalcancertreatedbyfolfoxfolfiriorxelox AT yanyanliu baselineserumuricacidlevelisassociatedwithprogressionfreesurvivaldiseasecontrolrateandsafetyinpostoperativepatientswithcolorectalcancertreatedbyfolfoxfolfiriorxelox AT jingrucheng baselineserumuricacidlevelisassociatedwithprogressionfreesurvivaldiseasecontrolrateandsafetyinpostoperativepatientswithcolorectalcancertreatedbyfolfoxfolfiriorxelox AT yifenwu baselineserumuricacidlevelisassociatedwithprogressionfreesurvivaldiseasecontrolrateandsafetyinpostoperativepatientswithcolorectalcancertreatedbyfolfoxfolfiriorxelox AT xiaoshanzhao baselineserumuricacidlevelisassociatedwithprogressionfreesurvivaldiseasecontrolrateandsafetyinpostoperativepatientswithcolorectalcancertreatedbyfolfoxfolfiriorxelox |